Lilly's 80-week trial in 1,298 adults with type 2 diabetes also showed bigger A1C drops. Dropout from side effects reached 7.9% on the higher dose versus 2.7% on Ozempic.
Recap by typeshit. Full story at BioPharm International.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
She sorts skincare peptides into three main groups, starting with signalling peptides that she says prompt more collagen production.
He says shedding tied to GLP-1 drugs usually passes, but can linger, and points to telogen effluvium triggered by fast weight loss.
Loading…